ICER finds anabolic agents not cost-effective to treat osteoporosis

19 June 2017

The Institute for Clinical and Economic Review (ICER) has released a new evidence report assessing the comparative effectiveness and value of Tymlos (abaloparatide), from US-based Radius Health (Nasdaq: RDUS) and Forteo (teriparatide), from Eli Lilly (NYSE: LLY).

The two anabolic agents were compared as treatments for osteoporosis in postmenopausal women who are at high risk for fracture.

The ICER’s analyses concluded that, when compared to no treatment, there is evidence that both therapies can provide a small or substantial net benefit, but there is not enough evidence to differentiate the two.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK